Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA

被引:31
作者
Butrapet, S [1 ]
Kinney, RA [1 ]
Huang, CYH [1 ]
机构
[1] US Dept HHS, Ctr Dis Control & Prevent, Publ Hlth Serv, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA
关键词
D O I
10.1016/j.jviromet.2005.06.019
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The genetic stabilities of the three attenuation loci of the candidate dengue 2 (D2) PDK-53 vaccine virus were evaluated for the PDK-53 virus and PDK-53-vectored chimeric D2/1 D2/3, and D2/4 viruses following 10 sequential passages in Vero cells. Sequencing revealed that the dominant NS1-53-Asp and the NS3-250-Val attenuation loci were extremely stable, whereas reversion occurred at the 5'NCR-57-U locus in 10 of the 18 viral lineages tested. A more sensitive and quantitative assay, the TaqMan mismatch amplification mutation assay (TaqMAMA), was employed to more finely discriminate the level of reversion at the 5'NCR-57 locus. This rapid genetic assay permitted detection of <= 1% reversion of YNCR-57 U-to-C in viral populations. By TaqMAMA, various levels of reversion at 5'NCR-57 were detected in all 18 of the PDK-53-based viral lineages tested at Vero passage 10, but only 3 lineages had reversion levels > 80% in the viral population. Chimeric viruses based on the PDK-53-V (all three Mutations present) genetic background were more stable than those developed in the PDK-53-E (5'NCR and NS I mutations present) background. The TaqMAMA can be applied in quality control analyses to ensure that attenuated vaccine seeds contain undetectable or minimal levels of reversion at a given attenuation locus. (c) 2005 Published by Elsevier B.V.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 23 条
[1]   ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy [J].
Arroyo, J ;
Miller, C ;
Catalan, J ;
Myers, GA ;
Ratterree, MS ;
Trent, DW ;
Monath, TP .
JOURNAL OF VIROLOGY, 2004, 78 (22) :12497-12507
[2]   Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay [J].
Bae, HG ;
Nitsche, A ;
Teichmann, A ;
Biel, SS ;
Niedrig, M .
JOURNAL OF VIROLOGICAL METHODS, 2003, 110 (02) :185-191
[3]  
BHAMARAPRAVATI N, 1987, B WORLD HEALTH ORGAN, V65, P189
[4]   Live attenuated tetravalent dengue vaccine [J].
Bhamarapravati, N ;
Sutee, Y .
VACCINE, 2000, 18 :44-47
[5]   Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge [J].
Bray, M ;
Men, RH ;
Lai, CJ .
JOURNAL OF VIROLOGY, 1996, 70 (06) :4162-4166
[6]   Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3 [J].
Butrapet, S ;
Huang, CYH ;
Pierro, DJ ;
Bhamarapravati, N ;
Gubler, DJ ;
Kinney, RM .
JOURNAL OF VIROLOGY, 2000, 74 (07) :3011-3019
[7]  
Butrapet Siritorn, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P589
[8]  
Cha R S, 1992, PCR Methods Appl, V2, P14
[9]   Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region [J].
Durbin, AP ;
Karron, RA ;
Sun, W ;
Vaughn, DW ;
Reynolds, MJ ;
Perreault, JR ;
Thumar, B ;
Men, R ;
Lai, CJ ;
Elkins, WR ;
Chanock, RM ;
Murphy, BR ;
Whitehead, SS .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 65 (05) :405-413
[10]   A novel assay for allelic discrimination that combines the fluorogenic 5′ nuclease polymerase chain reaction (TaqMan®) and mismatch amplification mutation assay [J].
Glaab, WE ;
Skopek, TR .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1999, 430 (01) :1-12